Q3 2017 13F Holders as of 9/30/2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.8M
-
Number of holders
-
83
-
Total 13F shares, excl. options
-
47.3M
-
Shares change
-
+1.05M
-
Total reported value, excl. options
-
$1.62B
-
Value change
-
+$33.5M
-
Put/Call ratio
-
10.01
-
Number of buys
-
39
-
Number of sells
-
-35
-
Price
-
$34.24
Significant Holders of Theravance Biopharma, Inc. - Common Stock (TBPH) as of Q3 2017
98 filings reported holding TBPH - Theravance Biopharma, Inc. - Common Stock as of Q3 2017.
Theravance Biopharma, Inc. - Common Stock (TBPH) has 83 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 47.3M shares
of 49.8M outstanding shares and own 95.04% of the company stock.
Largest 10 shareholders include Woodford Investment Management Ltd (10.7M shares), BAUPOST GROUP LLC/MA (9.31M shares), FMR LLC (7.9M shares), BlackRock Inc. (3.81M shares), VANGUARD GROUP INC (3.29M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.3M shares), FIRST MANHATTAN CO (1.61M shares), Cormorant Asset Management, LLC (950K shares), STATE STREET CORP (914K shares), and NORGES BANK (803K shares).
This table shows the top 83 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.